These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 37538495)

  • 1. Apixaban for treatment of venous thromboembolism in an obese patient with Glanzmann thrombasthenia.
    Sattler L; Wimmer J; Herb A; Gerout AC; Feugeas O; Desprez D
    Res Pract Thromb Haemost; 2023 May; 7(4):100183. PubMed ID: 37538495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes.
    Ballerie A; Nguyen Van R; Lacut K; Galinat H; Rousseau C; Pontis A; Nédelec-Gac F; Lescoat A; Belhomme N; Guéret P; Mahé G; Couturaud F; Jégo P; Gouin-Thibault I
    Thromb Res; 2021 Dec; 208():39-44. PubMed ID: 34689080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
    Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
    JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis.
    Dawwas GK; Brown J; Dietrich E; Park H
    Lancet Haematol; 2019 Jan; 6(1):e20-e28. PubMed ID: 30558988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editor's Choice - Severe Bleeding Risks of Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism: A Network Meta-Analysis of Randomised Controlled Trials.
    Chen J; Lv M; Wu S; Jiang S; Xu W; Qian J; Chen M; Fang Z; Zeng Z; Zhang J
    Eur J Vasc Endovasc Surg; 2022 Mar; 63(3):465-474. PubMed ID: 34973879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on extended treatment for venous thromboembolism.
    Peñaloza-Martínez E; Demelo-Rodríguez P; Proietti M; Soria Fernández-Llamazares G; Llamazares-Mendo C; Álvarez-Sala Walther L; Marra AM; Del Toro-Cervera J
    Ann Med; 2018 Dec; 50(8):666-674. PubMed ID: 30345825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis.
    Wang X; Ma Y; Hui X; Li M; Li J; Tian J; Wang Q; Yan P; Li J; Xie P; Yang K; Yao L
    Cochrane Database Syst Rev; 2023 Apr; 4(4):CD010956. PubMed ID: 37058421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic therapy for secondary prevention of unprovoked venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials.
    Li D; Liu Y; Song Y; Wen A
    Ann Med; 2022 Dec; 54(1):253-261. PubMed ID: 35023788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which patients with unprovoked venous thromboembolism should receive extended anticoagulation with direct oral anticoagulants? A systematic review, network meta-analysis, and decision analysis.
    Djulbegovic M; Lee AI; Chen K
    J Eval Clin Pract; 2020 Feb; 26(1):7-17. PubMed ID: 31190408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity.
    Crouch A; Ng TH; Kelley D; Knight T; Edwin S; ; Giuliano C
    Pharmacotherapy; 2022 Feb; 42(2):119-133. PubMed ID: 34904263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia.
    Di Minno G; Zotz RB; d'Oiron R; Bindslev N; Di Minno MN; Poon MC;
    Haematologica; 2015 Aug; 100(8):1031-7. PubMed ID: 26001793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity.
    Cohen A; Sah J; Lee T; Rosenblatt L; Hlavacek P; Emir B; Keshishian A; Yuce H; Luo X
    J Clin Med; 2021 Jan; 10(2):. PubMed ID: 33429844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Oral Anticoagulants in the Treatment of Acute Venous Thromboembolism: A Nationwide Comparative Cohort Study in France.
    Bertoletti L; Gusto G; Khachatryan A; Quignot N; Chaves J; Moniot A; Mokgokong R
    Thromb Haemost; 2022 Aug; 122(8):1384-1396. PubMed ID: 34983073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
    Robertson L; Yeoh SE; Ramli A
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data.
    Dawwas GK; Leonard CE; Lewis JD; Cuker A
    Ann Intern Med; 2022 Jan; 175(1):20-28. PubMed ID: 34871048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
    Cohen AT; Hamilton M; Bird A; Mitchell SA; Li S; Horblyuk R; Batson S
    PLoS One; 2016; 11(8):e0160064. PubMed ID: 27487187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.